Advanced Search
MyIDEAS: Login

Ongoing Pharmaceutical Reforms in France: Implications for Key Stakeholder Groups

Contents:

Author Info

  • Catherine Sermet

    (IRDES (Institut de recherche et de documentation en conomie de la sant), Paris, France)

  • Veronique Andrieu

    (Pharmacie Galnique Industrielle et Cosmtologie, Universit de la Mditerrane, Marseille, France)

  • Brian Godman

    (Institute for Pharmacological Research ‘Mario Negri’, Milan, Italy; University of Liverpool Management School, Liverpool, UK; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden)

  • Eric Van Ganse

    (Pharmacoepidemiology Unit, Centre Hospitalier Universitaire-Lyon, Lyon, France)

  • Alan Haycox

    (University of Liverpool Management School, Liverpool, UK)

  • Jean-Pierre Reynier

    (Pharmacie Galnique Industrielle et Cosmtologie, Universit de la Mditerrane, Marseille, France)

Abstract

The rapid rise in pharmaceutical costs in France has been driven by new technologies and the growing prevalence of chronic diseases as well as considerable prescribing freedom and choice of physician among patients. This has led to the introduction of a number of reforms and initiatives in an attempt to moderate expenditure whilst ensuring universal coverage and rewarding innovation. These reforms include accelerating access to and granting average European prices for new innovative drugs, delisting drugs where there are concerns over their value and instigating rebates for excessive prescribing. Alongside this, ongoing initiatives to improve the quality and efficiency of prescribing include programmes to enhance generic prescribing and dispensing as well as to reduce antibacterial and anxiolytic/hypnotic prescribing. However, there have been few publications documenting the impact of specific reforms on the overall costs and quality of care, which have been exacerbated by compartmentalization of budgets. Estimates suggest savings of over &U20AC;27 million/year by decreasing antibacterial prescribing, &U20AC;450 million/year by not reimbursing ineffective drugs, &U20AC;670 million/year from pharmaceutical company rebates and approximately &U20AC;1 billion/year from increased prescribing and dispensing of generics (year 2003-7 values). Additional savings of at least &U20AC;1.5 billion/year are seen as being possible from increased use of generics such as generic proton pump inhibitors, statins (HMG-CoA reductase inhibitors) and ACE inhibitors instead of current branded products such as angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]). Delisting drugs when there are concerns about their value provides an example to other countries with currently limited demand-side measures. Other possible examples include price : volume agreements and multifaceted campaigns to enhance generic prescribing and dispensing and reduce antibacterial prescribing. Possible future initiatives could include adopting more stringent criteria for categorizing new drugs as innovative as well as further reductions in the prices of generics. Other initiatives could include further enhancement of the quality and efficiency of prescribing, including formal auditing of physician prescribing, as well as increasing efforts to monitor the risk : benefit ratio of new drugs post-launch in real-world practice.

Download Info

If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
File URL: http://healtheconomics.adisonline.com/pt/re/ahe/pdfhandler.00148365-201008010-00002.pdf
Download Restriction: Pay per view
File URL: http://healtheconomics.adisonline.com/pt/re/ahe/fulltext.00148365-201008010-00002.htm
Download Restriction: Pay per view

As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

Bibliographic Info

Article provided by Springer Healthcare | Adis in its journal Applied Health Economics & Health Policy.

Volume (Year): 8 (2010)
Issue (Month): 1 ()
Pages: 7-24

as in new window
Handle: RePEc:wkh:aheahp:v:8:y:2010:i:1:p:7-24

Contact details of provider:
Web page: http://healtheconomics.adisonline.com/

Related research

Keywords: Health-policy;

Find related papers by JEL classification:

References

No references listed on IDEAS
You can help add them by filling out this form.

Citations

Lists

This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

Statistics

Access and download statistics

Corrections

When requesting a correction, please mention this item's handle: RePEc:wkh:aheahp:v:8:y:2010:i:1:p:7-24

For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

If references are entirely missing, you can add them using this form.

If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

Please note that corrections may take a couple of weeks to filter through the various RePEc services.